Life is hectic, we know, so here’s a recap of the Healthcare Weekly Hot Topics you can’t afford to miss:
1) EpiPen Manufacturer will be a No-Show at Senate Hearing. AP, November 21, 2016.
Mylan is refusing to testify on a settlement over its EpiPen.
2) CMS seeks to block supplemental Medicaid payments to providers. Modern Healthcare, November 21, 2016.
CMS wants to end supplemental funding that helped providers care for the poorest of people.
3) Novo, Sanofi go head to head as FDA clears new diabetes drugs. Reuters, November 22, 2016.
Rival companies won U.S. approval for new combination drugs to treat diabetes.
4) WHO declares end of Zika public health emergency. Healthcare IT News, November 22, 2016.
The Zika virus has been reclassified as a long-term epidemic, and is no longer a global public health emergency.
5) FDA Backs Off Plans to Issue Rules Governing Lab-Developed Tests. The Wall Street Journal, November 21, 2016.
The FDA planned to issue broad rules regarding laboratory tests performed by hospitals and private companies, but has now altered its plan.
Do you have questions about healthcare issues? We can help. For assistance, CLICK HERE.
Get “News You Can Use” delivered directly to your e-mail inbox. CLICK HERE TO SUBSCRIBE.
P.S. If you or your patients are interested in consumer healthcare issues, check out myhealthspin.com.
